...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Two big thank you’s

jonzobot - It looks like a fair argument could be made as to value today as .075 X 1.33 is .099 which happens to be just a little higher than the value of the shares at the time of the spin out. RVX on the other hand is dramatically lower today than it was at the time of the spin out. We'll cros that bridge when we get there...if we get there.

1.33 was the conversion rate yesterday.

tada 

Share
New Message
Please login to post a reply